RPLS induced by apatinib: a case report- Video Abstract ID 166605 скачать в хорошем качестве

RPLS induced by apatinib: a case report- Video Abstract ID 166605

Video abstract of case report “Reversible posterior leukoencephalopathy syndrome induced by apatinib: a case report and literature review” published in the open access journal OncoTargets and Therapy by Li X, Chai J, Wang Z, et al. Abstract: Reversible posterior leukoencephalopathy syndrome (RPLS) is a rare clinical-radiologic syndrome. There are reports that RPLS may be associated with cancer therapy including some chemotherapy drugs and antiangiogenic drugs. This paper reported a case of RPLS induced by apatinib, a vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase inhibitor. A 47-year-old cervical cancer patient was administered apatinib, and 3 months later, headache, dizziness, blurred vision, and hypertension appeared. She was diagnosed with RPLS by nuclear magnetic resonance imaging (MRI). After apatinib discontinuation and normotensive treatment, her symptoms completely reversed. Antiangiogenic drugs potentially damage the balance of the blood–brain barrier by directly injuring vascular endothelial cells, resulting in the occurrence of RPLS. This case is the first report of RPLS induced by apatinib. Read the case report here: https://www.dovepress.com/reversible-...